Latest Breaking News On - பீட்டர் கைசர் - Page 5 : comparemela.com

Press release content from PR Newswire. The AP news staff was not involved in its creation. Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial December 23, 2020 GMT CHENGDU, China, Dec. 23, 2020 /PRNewswire/ Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) to test the efficacy and safety of conbercept intravitreal injection in the treatment of neovascular age-related macular degeneration (“nAMD”). PANDA trials recently reached an important milestone by completing 36-week primary endpoint visits of enrolled patients. Conbercept is expected to launch globally in 2023, bringing a new treatment option to patients.

United statesPeter kaiserJeffrey heierPhilipj rosenfeldPrnewswire chengdu kanghong pharmaceutical groupSteering committeeDrug administrationEuropean medicine agencyChengdu kanghong pharmaceutical groupKanghong pharmaceutical groupAnnual american neovascularization conferenceConbercept phaseProfessor philipProtocol assessmentCleveland clinicOphthalmic consultants